Clinical Trials Browser

Phase 2 × Fibrosis × tremelimumab × Clear all

NCT05027425 2024-11-22

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Phase 2 Active not recruiting

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal